eNOS plays an important role in the regulation of colonic inflammation: A novel therapeutic target and a predictive marker for the prognosis of ulcerative colitis

Free Radical Research

Volumn 49, Issue 1, 2015, Pages 35-44

  Okaniwa, N ^a   Sasaki, Makoto ^a   Mizushima, T ^b   Ogasawara, N ^a   Funaki, Y ^a   Joh, T ^c   Kasugai, K ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Gastroenterology Gifu Prefectual Tajimi Hospital   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Endothelial adhesion molecules; eNOS over expression; Gene polymorphism; Inflammatory bowel disease; Intractable case

Indexed keywords

BIOLOGICAL MARKER; DEXTRAN SULFATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; MYELOPEROXIDASE; STEROID; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; CELL ADHESION MOLECULE; NOS3 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C3H/HE MOUSE; CLINICAL FEATURE; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DNA POLYMORPHISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOUSE; NONHUMAN; PROGNOSIS; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEROID THERAPY; TRANSGENIC MOUSE; ULCERATIVE COLITIS; WILD TYPE; ANIMAL; BIOSYNTHESIS; C3H MOUSE; CELL LINE; COLITIS, ULCERATIVE; DISEASE MODEL; ENZYMOLOGY; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CELL LINE; CELL LINE, TUMOR; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C3H; MICE, TRANSGENIC; NITRIC OXIDE SYNTHASE TYPE III; PROGNOSIS; TRANSFECTION;

EID: 84915756401     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2014.977788     Document Type: Article

References (52)

1. Loftus EV Jr. Clinical epidemiology of infl ammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517.
2. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2014;27:1266-1280.
3. Schirbel A, Fiocchi C . Infl ammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis 2010;11:266-276.
4. Yamamoto T. Nutrition and diet in inflammatory bowel disease. Curr Opin Gastroenterol 2013;29:216-221.
5. Uchiyama K, Odahara S, Nakamura M, Koido S, Katahira K, Shiraishi H, et al. The fatty acid profile of the erythrocyte membrane in initial-onset infl ammatory bowel disease patients. Dig Dis Sci 2013;58:1235-1243.
6. Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, et al. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005;11:154-163.
7. Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J Gastroenterol 1995;30 Suppl 8:5-8.
8. Granger DN, Kubes P . The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662-675.
9. Sasaki M, Bharwani S, Jordan P, Elrod JW, Grisham MB, Jackson TH, et al. Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radic Biol Med 2003;35:1679-1687.
10. Sasaki M, Bharwani S, Jordan P, Joh T, Manas K, Warren A, et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis. J Pharmacol Exp Ther 2003;305:78-85.
11. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110.
12. Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with infl ammatory bowel disease. Gut 1999;45:856-863.
13. Oshima T, Jordan P, Grisham MB, Alexander JS, Jennings M, Sasaki M, Manas K. TNF-alpha induced endothelial MAd-CAM-1 expression is regulated by exogenous, not endogenous nitric oxide. BMC Gastroenterol 2001;1:5.
14. Forstermann U, Boissel JP, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). Faseb J 1998;12:773-790.
15. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999;43:521-531.
16. Yu J, Zhang Y, Zhang X, Rudic RD, Bauer PM, Altieri DC, Sessa WC. Endothelium derived nitric oxide synthase negatively regulates the PDGF-survivin pathway during flow-dependent vascular remodeling. PLoS One 2012;7:e31495.
17. Binion DG, West GA, Volk EE, Drazba JA, Ziats NP, Petras RE, Fiocchi C. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998;352:1742-1746.
18. Guihot G, Guimbaud R, Bertrand V, Narcy-Lambare B, Couturier D, Duee PH, et al. Inducible nitric oxide synthase activity in colon biopsies from infl ammatory areas: correlation with infl ammation intensity in patients with ulcerative colitis but not with Crohn's disease. Amino Acids 2000;18:229-237.
19. Binion DG, Rafiee P, Ramanujam KS, Fu S, Fisher PJ, Rivera MT, et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med 2000;29:881-888.
20. Hatoum OA, Binion DG, Otterson MF, Gutterman DD . Acquired microvascular dysfunction in infl ammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125:58-69.
21. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001;32:980-986.
22. Atochin DN, Huang PL . Endothelial nitric oxide synthase transgenic models of endothelial dysfunction. Pflugers Arch 2010;460:965-974.
23. Huang SS, Wei FC, Hung LM . Ischemic preconditioning attenuates postischemic leukocyte-endothelial cell interactions: role of nitric oxide and protein kinase C. Circ J 2006;70:1070-1075.
24. Kaminski A, Pohl CB, Sponholz C, Ma N, Stamm C, Vollmar B, Steinhoff G. Up-regulation of endothelial nitric oxide synthase inhibits pulmonary leukocyte migration following lung ischemia-reperfusion in mice. Am J Pathol 2004;164:2241-2249.
25. Lefer DJ, Jones SP, Girod WG, Baines A, Grisham MB, Cockrell AS, et al. Leukocyte-endothelial cell interactions in nitric oxide synthase-defi cient mice. Am J Physiol 1999;276(6 Pt 2):H1943-1950.
26. Chen F, Lucas R, Fulton D. The subcellular compartmentalization of arginine metabolizing enzymes and their role in endothelial dysfunction. Front Immunol 2013;4:184.
27. Dijkstra G, Moshage H, van Dullemen HM, de Jager-Krikken A, Tiebosch AT, et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in infl ammatory bowel disease. J Pathol 1998;186:416-421.
28. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, et al. T-786->C mutation in the 5′- flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99:2864-2870.
29. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003;49:389-395.
30. Inaba Y, Chen JA, Bergmann SR . Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis . Int J Cardiovasc Imaging 2010;26:631-640.
31. O'Connell KA, Edidin M. A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J Immunol 1990;144:521-525.
32. Ohashi Y, Kawashima S, Hirata K, Yamashita T, Ishida T, Inoue N, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998;102:2061-2071.
33. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385-391.
34. Grisham MB, Benoit JN, Granger DN . Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol 1990;186:729-742.
35. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607.
36. Wang J, Dudley D, Wang XL. Haplotype-specifi c eff ects on endothelial NO synthase promoter efficiency:modifi able by cigarette smoking. Arterioscler Thromb Vasc Biol 2002;22:e1-4.
37. National Center for Biotechnology Ingormation [Internet]. 41322052-SNP-NCBI. Available from:http://http://www.ncbi.nlm.nih.gov/snp/?term=2070744 [cited 2014 Aug 11].
38. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS. eNOS activity is reduced in senescent human endothelial cells:Preservation by hTERT immortalization. Circ Res 2001;89:793-798.
39. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells J Atheroscler Thromb 2002;9:178-183.
40. Naito Y, Katada K, Takagi T, Tsuboi H, Isozaki Y, Handa O, et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med 2006;17:997-1004.
41. Suematsu M, Tamatani T, Delano FA, Miyasaka M, Forrest M, Suzuki H, et al. Microvascular oxidative stress preceding leukocyte activation elicited by in vivo nitric oxide suppression. Am J Physiol 1994;266:H2410-H2415.
42. Shen C, Dillissen E, Kasran A, Lin Y, Herman J, Sienaert I, et al. Immunosuppressive activity of a new pteridine derivative (4AZA1378) alleviates severity of TNBS-induced colitis in mice. Clin Immunol 2007;122:53-61.
43. Kawashima S . Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. J Pharmacol Sci 2004;96:411-419.
44. Edgar K, Gardiner TA, van Haperen R, de Crom R, McDonald DM. eNOS overexpression exacerbates vascular closure in the obliterative phase of OIR and increases angiogenic drive in the subsequent proliferative stage. Invest Ophthalmol Vis Sci 2012;53:6833-6850.
45. Bendall JK, Alp NJ, Warrick N, Cai S, Adlam D, Rockett K, et al. Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo: insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression. Circ Res 2005;97:864-871.
46. Aroca R, Chamorro C, Vega A, Ventura I, Gomez E, Perez-Cano R, et al. Immunotherapy reduces allergen-mediated CD66b expression and myeloperoxidase levels on human neutrophils from allergic patients. PLoS One 2014;9:e94558.
47. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M, et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2004;286:H276-H282.
48. Ishihara T, Tanaka K, Tasaka Y, Namba T, Suzuki J, Ishihara T, et al. Therapeutic effect of lecithinized superoxide dismutase against colitis. J Pharmacol Exp Ther 2009;328:152-164.
49. Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M, et al. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T->C mutation associated with coronary spastic angina. Hum Mol Genet 2000;9:2629-2637.
50. International HapMap Priject [Internet]. HapMap: SNP report for rs2070744. Available from:http://hapmap.ncbi.nlm.nih.gov/cgi-perl/snp-details-B36?name=rs2070744&source=hapmap24-B36. [cited 2014 Aug 11].
51. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
52. Parkes M, Satsangi J, Jewell D. Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clin Exp Immunol 1998;113:28-32.